Clinical Trial

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

Study acronym: WinGlio-ipi
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer). Participants will receive up to 2 cycles of ipilimumab prior to the standard of care treatments for this patient group which can include debulking surgery and chemoradiation. The aim of giving the ipilimumab to the participants is to see if it is safe to treat patients with this condition with ipilimumab and also to see if the drug helps to reduce or control the patient's disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-14.
Trial Details
NCT Number NCT07134842
Lead Sponsor University College, London
Conditions Glioblastoma, Gliosarcoma, Adult, Glioblastoma - Category
Enrollment 16 participants
Start Date 2025-07-10
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-09